SynthesisFrontiers in medicine2020
Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept.
Synthesis in Frontiers in medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Experience and Needs of Immunotherapy for Lung Cancer Patients: A Meta-Synthesis of Qualitative Studies.Psycho-oncology · 2025Pooled it
- Tumor-infiltrating natural killer cell profiling for therapeutic stratification in patients with resectable non-small cell lung cancer.The Journal of thoracic and cardiovascular surgery · 2026Article
- Postoperative survival in patients undergoing surgery for long bone metastases: a systematic review and Meta-analysis of outcomes across primary tumor types.Journal of bone oncology · 2026Review
- Treatment Patterns Across Lines of Therapy for Advanced Non-Small Cell Lung Cancer in the United States.Cancer medicine · 2026Article
- Graph neural network modeling of spatial tumor-immune interactions identifies prognostic cellular niches in non‑small cell lung cancer.NPJ precision oncology · 2026Article
- Proof of Concept for Tumor Mutational Burden Prediction Through Biophysical Analysis Based on UHF-Dielectrophoresis.Biosensors · 2026Article
- Cemiplimab in Japanese patients with advanced non-small cell lung cancer.Japanese journal of clinical oncology · 2026Article
- Tumor-infiltrating natural killer cell profiling for therapeutic stratification in patients with resectable non-small cell lung cancer.bioRxiv : the preprint server for biology · 2026Article
- Does neoadjuvant chemoimmune therapy confer benefits to all NSCLC patients?Future oncology (London, England) · 2025Article
- Overcoming resistance to immune checkpoint inhibitor in non-small cell lung cancer: the promise of combination therapy.Frontiers in immunology · 2025Review
- Combination Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer: A Review of Evidence.Cancer medicine · 2024Review
- Article
- Integrative Approaches in Non-Small Cell Lung Cancer Management: The Role of Radiotherapy.Journal of clinical medicine · 2024Review
- Targeted inhibition of the HNF1A/SHH axis by triptolide overcomes paclitaxel resistance in non-small cell lung cancer.Acta pharmacologica Sinica · 2024Article
- WhARIO: whole-slide-image-based survival analysis for patients treated with immunotherapy.Journal of medical imaging (Bellingham, Wash.) · 2024Article
- CXCL13 Positive Cells Localization Predict Response to Anti-PD-1/PD-L1 in Pulmonary Non-Small Cell Carcinoma.Cancers · 2024Article
- Niclosamide improves cancer immunotherapy by modulating RNA-binding protein HuR-mediated PD-L1 signaling.Cell & bioscience · 2023Article
- Review
- Powering single-cell genomics to unravel circulating tumour cell subpopulations in non-small cell lung cancer patients.Journal of cancer research and clinical oncology · 2023Article
- The Current Landscape of Immune Checkpoint Inhibitor Immunotherapy for Primary and Metastatic Brain Tumors.Antibodies (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunotherapy in lung cancer treatment is a long history paved with failures and some successes. During the last decade, the discovery of checkpoints inhibitors led to major advances in treating advanced and metastatic non-small cell lung cancer (NSCLC). Impressive data from early phase I-II studies were subsequently confirmed in large prospective randomized trials and meta-analyses (High-level of evidence). Three anti- programmed death-1 (PD1) (pembrolizumab, nivolumab) or antiPD-ligand(L)1 (atezolizumab) antibodies showed clinically significant improved survival compared to second-line docetaxel. Then, first-line pembrolizumab monotherapy demonstrated its superiority over platinum-doublet in high PD-L1 NSCLC. The addition of pembrolizumab or atezolizumab to chemotherapy derived the same results regardless of the PD-L1 status. On the opposite, antiCTLA4 (Cytotoxic T-Lymphocyte Associated 4) results are currently disappointing in unselected patients while recent development suggest that the combination of antiPD1 and antiCTLA4 (nivolumab-ipilimumab) positively impact on overall survival. Some secondary analyses also showed that immunotherapy has a positive impact on quality of life and that the clinical improvement can be done at an acceptable incremental cost per QALY. A lot of questions remain unresolved: which is the best treatment duration and is it the same for all patients, how to choose the patients that will have the highest benefit of immunotherapy, how to identify the patients who will have rapid progression, how to improve the current data (new targets, new combinations)….
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.